Ketazolam

Summary

Ketazolam (CHEMBL2104356) is an approved small molecule (ATC N05BA10); indicated across 1 condition including anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05BA10
• Indications: 1 condition
• Chemistry: 368.8 Da · C20H17ClN2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104356
Name	Ketazolam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	33746
ATC	N05BA10
Molecular formula	C20H17ClN2O3
Molecular weight	368.8
InChIKey	PWAJCNITSBZRBL-UHFFFAOYSA-N

SMILES: CC1=CC(=O)N2CC(=O)N(C3=C(C2(O1)C4=CC=CC=C4)C=C(C=C3)Cl)C

IUPAC name: 11-chloro-2,8-dimethyl-12b-phenyl-6H-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7-dione

Also known as: Anseren, Ansieten, Anxon, Contamex, Ketazolam, Loftran, NSC-338158, U-28,774, U-28774, Unakalm, KETAZOLAM

Patent coverage: 669 distinct patent families (2,652 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,618 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anxiety	4	MONDO:0011918	EFO:0005230

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).